Chimerix (CMRX) to Release Earnings on Thursday

Chimerix (NASDAQ:CMRX) is scheduled to announce its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) EPS for the quarter, meeting the consensus estimate of ($0.23). The firm had revenue of $0.13 million for the quarter, compared to the consensus estimate of $1.26 million. During the same quarter in the previous year, the business earned ($0.21) earnings per share. On average, analysts expect Chimerix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Chimerix Trading Up 6.1 %

Chimerix stock traded up $0.06 during mid-day trading on Tuesday, hitting $1.05. The stock had a trading volume of 158,145 shares, compared to its average volume of 351,777. Chimerix has a one year low of $0.75 and a one year high of $1.30. The firm has a market capitalization of $94.12 million, a P/E ratio of -1.04 and a beta of 1.13. The firm’s 50 day moving average is $0.90 and its 200 day moving average is $0.91.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Chimerix in a research note on Wednesday, August 14th. StockNews.com upgraded Chimerix from a “sell” rating to a “hold” rating in a research note on Wednesday, August 21st. Finally, Wedbush reaffirmed an “outperform” rating and set a $6.00 price objective on shares of Chimerix in a report on Tuesday, August 13th.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.